Long-Term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-Severe Dementia Associated With Parkinson's Disease (PDD) - Full Text View

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00623103

Purpose

The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.

Condition	Intervention	Phase
Dementia Associated With Parkinson's Disease	Drug: Rivastigmine capsule Drug: Rivastigmine transdermal patch	Phase III

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics: Dementia Parkinson's Disease

Drug Information available for: Rivastigmine SDZ-ENA 713

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	A 76-Week Prospective, Open-Label, Multicenter Study to Evaluate the Long-Term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Further study details as provided by Novartis:

Primary Outcome Measures:

Predefined adverse events (AEs) due, or potentially due, to worsening of PD motor symptoms (tremor, muscle rigidity, bradykinesia, fall) [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]
Study drug discontinuations due to predefined AEs that are due, or potentially due, to worsening of PD motor symptoms (tremor, muscle rigidity, bradykinesia, fall) [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Change in Unified Parkinson Disease Rating Scale (UPDRS) Part III motor examination scores at Weeks 8, 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 8, 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: Yes ]
Change in Mattis Dementia Rating Scale (Mattis DRS-2) scores at Weeks 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: No ]
Change in Ten Point Clock Test (TPCT) scores at Weeks 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: No ]
Change in Neuropsychiatric Inventory-10 (NPI-10) scores at Weeks 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: No ]
Change in Alzheimer's Disease Cooperative Study-Activities Of Daily Living (ADCS-ADL) scores at Weeks 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: No ]
Change in UPDRS Part V stage (Modified Hoehn and Yahr Staging)at Weeks 16, 24, 52 and 76 (or early discontinuation) compared to baseline [ Time Frame: At Weeks 16, 24, 52 and 76 (or early discontinuation) ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	550
Study Start Date:	January 2008
Estimated Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Rivastigmine capsule
2: Experimental	Drug: Rivastigmine transdermal patch

Eligibility

Ages Eligible for Study:	50 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of idiopathic Parkinson's disease, according to the UK Parkinson's disease Society Brain Bank criteria
Diagnosis of Parkinson's disease dementia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, with onset of symptoms of dementia at least 2 years following the first diagnosis of idiopathic Parkinson's disease
Mini Mental State Examination score of ≥10 and ≤ 24 (at Screening Visit only)

Exclusion Criteria:

An advanced, severe, or unstable disease of any type that may interfere with the primary and secondary variable evaluations
A score of 5 (wheelchair bound or bedridden) in the "on"-state on the Modified Hoehn and Yahr Staging (UPDRS Part V)
A current diagnosis of any primary neurodegenerative disorder other than idiopathic PD
A current diagnosis of any treatable dementia (hypothyroidism, syphilis, vitamin B12 or folate deficiency) that is verified by the investigator to be the cause of dementia.
A current diagnosis of probably vascular dementia according to the National Institute of Neurological Disorders and Stroke and the Association International pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria
A current diagnosis of a major depressive episode according to DSM-IV criteria
A history of stereotaxic brain surgery for Parkinson's disease
A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to rivastigmine or to other cholinergic compounds

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00623103

Contacts

Contact: Novartis

+41 61 324 1111

Show 113 Study Locations

Sponsors and Collaborators

Novartis

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

Responsible Party:	Novartis ( External Affairs )
Study ID Numbers:	CENA713B2315
Study First Received:	February 14, 2008
Last Updated:	November 20, 2008
ClinicalTrials.gov Identifier:	NCT00623103
Health Authority:	United States: Food and Drug Administration; Canada: Health Canada; Austria: Agency for Health and Food Safety; Belgium: Federal Agency for Medicinal Products and Health Products; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Italy: Ministry of Health; Netherlands: Medicines Evaluation Board (MEB); Spain: Spanish Agency of Medicines; Turkey: Ministry of Health; United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:

Parkinson's disease dementia
cholinesterase inhibitor
rivastigmine

Study placed in the following topic categories:

Ganglion Cysts
Rivastigmine
Basal Ganglia Diseases
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Cognition Disorders

Delirium, Dementia, Amnestic, Cognitive Disorders
Parkinson Disease
Movement Disorders
Mental Disorders
Parkinsonian Disorders
Dementia
Delirium

Additional relevant MeSH terms:

Cholinesterase Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs
Nervous System Diseases

Enzyme Inhibitors
Cholinergic Agents
Central Nervous System Agents
Protective Agents
Neuroprotective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009